Apnimed, Inc. APMD
15.10 USD +0.94 (+6.64%)
At closeNov 6, 2026, 4:01 PM EST
15.10 0.00 0.00%
After hours · Nov 6, 4:01 PM ET
14.11 Day range 15.41
14.16 52-week range 32.55
- YTD
- -39.60%
- 1 year
- -39.60%
- Market cap
- 628.62M
- Revenue (ttm)
- 115.12M
- Profit margin
- 142.10%
- EPS (ttm)
- 7.22
- Shares out
- 41.63M
- P/E ratio
- 2.09
- Forward P/E
- -6.42
- YTD return
- -39.60%
- 1-year return
- -39.60%
- Volume
- 225.37K
- Avg volume
- 468.15K
- Open
- 14.26
- Previous close
- 14.16
- Day's range
- 14.11 – 15.41
- 52-week range
- 14.16 – 32.55
- Analysts
- Strong Buy
- Price target
- 50.33 (+233.3%)
5D -1.35 (-8.21%)
Key statistics
- Enterprise value
- 1.25B
- PEG ratio
- 0.00
- Price / sales
- 9.23
- Price / book
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- -29.40%
- Free cash flow
- 0
- Total cash
- 172.80M
- Total debt
- 80.35M
- Return on equity
- 0.00%
- Short % of float
- 0.00%
- 50-day average
- 27.74
- 200-day average
- 27.74
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 50.33 +233.3% upside
Now 15.10
- Target (low)
- 41.00
- Target (mean)
- 50.33
- Target (high)
- 60.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy0
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34.
Financials — quick view
APMD Revenue — quarterly 12.08M
APMD Net income — quarterly 125.94M
APMD EPS — quarterly 26.25
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Sep 8, 2026 | Jun 30, 2026 | -0.48667 | 3.92 | +4.41 | +905.47% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 25, 2026 | LifeSci Capital | init | — | Outperform |
| Aug 25, 2026 | Cantor Fitzgerald | init | — | Overweight |
| Aug 25, 2026 | Evercore ISI Group | init | — | Outperform |
| Aug 25, 2026 | B of A Securities | init | — | Buy |
About Apnimed, Inc.
Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- apnimed.com
News
No recent headlines
Headlines appear here as they are published.
Your note
Sign in to keep a note on APMD — it syncs with the Stock Master app.